Fig. 1. Schematic illustration of the design of I-PCLU and preparation of Dox-loaded beads.

Fig. 2. Optical morphology and size distribution of unloaded and Dox-loaded I-PCLU beads (the scale bar in optical images was 1 mm).

Fig. 3. Surface and inner microstructure of (a-c) I-PCLU-121/Dox and (d-f) I-PCLU-132/Dox beads.

Fig. 4. Fluorescent microscopy image and the corresponding fluorescent intensity of doxorubicin-loaded beads, (a) I-PCLU-121/DOX and (b) I-PCLU-132/DOX beads.

Fig. 5. Accumulated release curves of I-PCLU-121/Dox and I-PCLU-132/Dox beads, and the X-ray images of Dox-loaded beads before and after releasing was inset in the release curves.

Fig. 6. MTT assay of tumor cell inhibition effect on I-PCLU-121/Dox and I-PCLU-132/Dox (TCPS and Dox were set as negative and positive group).

Fig. 7. The cell viability of drug-loaded I-PCLU-121 and I-PCLU-132 beads after 24 h (a-d) and 72 h (e-h) Hela culture (TCPS and Dox were set as negative and positive group).

Fig. 8. Photographs of I-PCLU-121 beads within rabbit muscle after (a) one and (b) four weeks implantation.

Fig. 9. Toxicity evaluation of the as-prepared blank beads via in vivo toxicity test. Histological section of tissues contained beads (a, c) I-PCLU-121 and (b, d) I-PCLU-132 beads after one and four weeks’ implantation (the arrows pointing the implanted microspheres, the magnification was ×100).

Fig. 10. (a), (b) Radiopaque signal and (c) CT scan images recorded of I-PCLU-132/Dox beads at the delay period (1 h later); (d)-(j) Radiopaque signal of contrast agent at gastric area; (k), (l) Radiopaque signal of contrast agent at kidney area.

Fig. 11. CT scan images presented the tumors volume changes: (a), (b) The control group rabbit with normal breeding; (c), (d) The experimental group rabbit with interventional therapy. The numbers in each image show tumor volume and the relative changes compared to their original volume.